Acurx Pharmaceuticals (ACXP) Registration Filing summary

Company overview and business model

• Focuses on developing a new class of small molecule antibiotics targeting difficult-to-treat Gram-positive bacterial infections, including priority pathogens identified by WHO, CDC, and FDA.

• Pipeline includes candidates for Clostridioides difficile, MRSA, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae.

• Organized in Delaware in 2017, commenced operations in 2018, and converted to a corporation in 2021.

Financial performance and metrics

• As of December 30, 2025, had 2,348,113 shares of common stock outstanding and no preferred stock outstanding.

• Aggregate market value of public float was $12,384,849 as of the prospectus date.

• Sold $5.5 million of securities in the prior 12 months under Form S-3.

• Audit report includes a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including clinical trials, R&D, working capital, capital expenditures, investments, acquisitions, and collaborations.

• Management has broad discretion over allocation and may invest proceeds in short-term, investment-grade securities or reduce short-term debt.